Buehlmann


The Royal Berkshire Hospital, Reading

Just a sample image

Quantum Blue® Testimonial

Dr. Tracey Staughton is working as a clinical scientist in the Biochemistry Departement of the Royal Berkshire Hospital in Reading, UK. She is, among other projects, responsible for the calprotectin determinations at this hospital.
Tracey and her team have adopted the BÜHLMANN Calprotectin Rapid test Quantum Blue® in 2010 and are now routinely providing calprotectin results for the gastroenterology department.

Interview with TraceyStaughton, Clinical Scientist


Since when and why are you using the Quantum Blue® System by BÜHLMANN?

Evaluation of Quantum Blue Calprotectin started in October 2010 following attendance at FOCUS 2010 where the Quantum Blue system was exhibited.

Until this point, any Calprotectin requests received from within the hospital where sent to Kings College Hospital, London where results were turned round in approx. 14 days. At this time we were seeing around 1 sample per month so this service was more than adequate.

During 2009, the number of requests began to rise and during 2010 it was decided that we should look at bringing the test in-house and reconsider its place in our diagnostic pathways based on the lead given by King’s in this area. The Quantum Blue Calprotectin test and reader made this decision easier.


Did you evaluate comparability of the Quantum Blue® with the BÜHLMANN calprotectin ELISA results from King’s College hospital?

Yes, the introduction of the Quantum Blue® has allowed us to process the samples as they arrive into the department quickly and easily and provided us with results that compared well to those generated at Kings, which are run with the calprotectin ELISA.

Could you introduce this new technique without any delay?

Introduction of Quantum Blue® into the department has been very easy. Staff like using the system and the extraction step is made as easy and straightforward as it can be using the Smart Prep device also supplied by Alpha Labs and validated for use with the Quantum Blue® tests.

test












Who is requesting the calprotectin results from your laboratory?

At the Royal Berkshire NHS Foundation Trust, we have 4 Consultant Gastroenterologists and all of our Calprotectin requests are generated from within the hospital. We do sometimes receive requests from General Practitioners, but these are at the specific request of a member of our Gastroenterology team.

Will the requests expand to outside the Royal Berkshire hospital and to paediatricians?

We do not currently receive requests from our GP population, but this may change depending upon future funding arrangements. We are also seeing an increased number of requests being generated by the paediatric team.

Did you already start to have requests for IBD therapy surveillance?

Yes, in terms of clinical utility, the test is being used to monitor treatment in our Crohn’s patients and to aid differential diagnosis between irritable bowel disease and inflammatory bowel disorder.

How do you manage data interpretation?

In terms of reporting of results, we currently use a cut-off level of 60 ug/g and do not comment on the results obtained. Clinical interpretation is carried out by the relevant Gastroenterologist. The service provided is currently the subject of an internal Audit exercise and we are awaiting results of this.

Thank you for this interview.

Contact

BÜHLMANN Laboratories AG
Baselstr. 55
CH-4124 Schönenbuch
Switzerland
Fon: +41 61 487 12 12
Fax: +41 61 487 12 34
info@buhlmannlabs.ch

Your local distributor
Order
About us
Job opportunities

News

The recently launched EntroGen BRAF (V600E/K/D) test, that can be run on your real-time PCR instrument, is now CE-IVD marked

The EntroGen BRAF (V600E/K/D) test is a very useful tool for the detection of important mutations found in melanoma, because it detects, beside the V600E  more

INFINITI KRAS-BRAF study from the Basel Institut of Pathology published in the Diagnostic Molecular Pathology journal.

New publication about the INFINITI KRAS assay in the Journal Diagn Mol Path 21/1 2012 14-23, Bihl et al. In this study from the Institute of Pathology at  more

Recent publications on BÜHLMANN calprotectin assays

Three very interesting new papers have been published recently. Manz et al. describes the quality and usefulness of the BÜHLMANN calprotectin ELISA in an  more

NEW OWN CALPROTECTIN REIMBURSEMENT POSITION IN SWITZERLAND

BÜHLMANN is very proud to announce that the calprotectin determination in stool starting from January 1st 2012, has an official new position in the reimb  more

Get our RSS - Feed